Alzamend Neuro (ALZN) insiders report 166,909 shares (4.4%)

Alzamend Neuro, Inc. holders led by Milton C. Ault III report combined beneficial ownership of 166,909 shares, representing approximately 4.4% of the company's 3,739,861 outstanding shares as of October 7, 2025.

Rhea-AI Filing Summary

Alzamend Neuro, Inc. holders led by Milton C. Ault III report combined beneficial ownership of 166,909 shares, representing approximately 4.4% of the company's 3,739,861 outstanding shares as of October 7, 2025. The filing aggregates direct holdings, shares underlying Series B convertible preferred stock and exercisable warrants, and stock options across related entities including Hyperscale Data, Ault Lending, Ault Life Sciences and others.

The statement breaks out voting and dispositive power: Mr. Ault holds 1,843 shares directly and shared voting power over 165,066 shares; Hyperscale Data and Ault Lending each report beneficial ownership of roughly 153,937 and 153,925 shares respectively (about 4.0%). Purchase prices for several block holdings are disclosed in aggregate dollar amounts, and no transactions in the past 60 days are reported except as listed in an exhibit.

Positive

• Transparent disclosure of beneficial ownership breakdown across direct shares, warrants, preferred, and options
• Detailed voting/dispositive power numbers clarify who controls decision rights (e.g., 165,066 shared voting power for Mr. Ault)
• Purchase prices disclosed for several holdings, enabling investor traceability of stake cost basis

Negative

• Concentration of shared voting power through affiliated entities could amplify influence without a large direct economic stake
• Potential dilution from conversion of Series B preferred and exercisable warrants could change ownership percentages
• Limited recent trading transparency—no transactions in past 60 days reported except Exhibit 1, requiring review for activity details

Insights

Equity Ownership Analyst

Insider group holds a modest 4.4% stake through a mix of equity and convertible instruments.

The ownership combines direct common shares, shares underlying Series B convertible preferred stock and currently exercisable warrants, plus options. The conversion and warrant components concentrate control within related entities, increasing the reporting persons' effective influence beyond direct share counts.

Primary dependencies are the conversion terms of the Series B instruments and warrant exercise conditions; if exercised, the effective common share count and dilution profile will change. Monitor any amendments to conversion limits or additional filings around exercise events within the next 60–180 days.

Corporate Governance Specialist

Shared voting power signals coordinated control via affiliated entities rather than a single direct block.

The filing shows shared voting power of 165,066 shares attributable to Mr. Ault through affiliated vehicles, which centralizes decision-making influence despite a sub-5% economic stake. That structure can affect board elections or consent matters if other owners are fragmented.

Risks include potential future aggregation of economic and voting power if warrants or preferred shares convert; any proxy solicitations or related-party transactions would likely surface in subsequent filings and should be reviewed over the coming quarters.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Milton C. Ault III report in Alzamend Neuro (ALZN)?

Mr. Ault may be deemed to beneficially own 166,909 shares, representing about 4.4% of outstanding shares as of October 7, 2025.

How much of ALZN does Hyperscale Data, Inc. beneficially own?

Hyperscale Data may be deemed to beneficially own 153,937 shares, approximately 4.0% of the outstanding shares.

What instruments contribute to the reported ownership percentages?

The counts include direct common shares, shares underlying Series B convertible preferred stock, currently exercisable warrants, and stock options exercisable within 60 days.

What is the total number of ALZN shares outstanding used to calculate percentages?

Percentages are based on 3,739,861 shares outstanding as reported to the reporting persons.

Did the reporting persons trade ALZN stock in the past 60 days?

The filing states no transactions in the past 60 days by the reporting persons except as set forth in Exhibit 1 to the filing.

Are purchase prices for the reported holdings disclosed?

Yes; several aggregate purchase prices are provided, for example $159,727 for 68,848 shares held by Ault Lending and $7,970 for 11,068 shares held by Ault Life Sciences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 09:53 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 11)

Alzamend Neuro, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

02262M605

(CUSIP Number)

MILTON C. AULT, III
c/o HYPERSCALE DATA, INC. 11411 SOUTHERN, HIGHLANDS PARKWAY, SUITE 190
Las Vegas, NV, 89141
(949) 444-5464

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/03/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

MILTON C. AULT, III

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,843.00
8	Shared Voting Power 165,066.00
9	Sole Dispositive Power 1,843.00
10	Shared Dispositive Power 165,066.00

11

Aggregate amount beneficially owned by each reporting person

166,909.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Sole voting and dispositive power represents shares of Common Stock. Shared voting and dispositive power represents (i) 61,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock held by Ault Lending, LLC, (ii) 23,334 shares of Common Stock underlying currently exercisable warrants held by Ault Lending, LLC, (iii) 68,848 shares of Common Stock held by Ault Lending, LLC, (iv) 11,068 shares of Common Stock held by Ault Life Sciences, Inc., (v) 61 shares of Common Stock held by Ault Life Sciences Fund, LLC, and (vi) 12 shares of Common Stock underlying currently exercisable warrants held by Hyperscale Data, Inc.

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

WILLIAM B. HORNE

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,518.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,518.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,518.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Represents (i) 3,333 shares of Common Stock and (ii) 185 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

HENRY C.W. NISSER

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SWEDEN

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 926.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 926.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

926.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Represents shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

KENNETH S. CRAGUN

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,111.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,111.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,111.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Represents shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

DAVID J. KATZOFF

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,726.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,726.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,726.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Represents (i) 615 shares of Common Stock and (ii) 1,111 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

HYPERSCALE DATA, INC.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 153,937.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 153,937.00

11

Aggregate amount beneficially owned by each reporting person

153,937.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.0 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Represents (i) 12 shares of Common Stock underlying currently exercisable warrants held by it, (ii) 61,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock held by Ault Lending, LLC, (iii) 23,334 shares of Common Stock underlying currently exercisable warrants held by Ault Lending, LLC, and (iv) 68,848 shares of Common Stock held by Ault Lending, LLC.

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

AULT LENDING, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 153,925.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 153,925.00

11

Aggregate amount beneficially owned by each reporting person

153,925.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.0 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Represents (i) 68,848 shares of Common Stock, (ii) 61,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock and (iii) 23,334 shares of Common Stock underlying currently exercisable warrants.

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

AULT LIFE SCIENCES, INC.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 11,068.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 11,068.00

11

Aggregate amount beneficially owned by each reporting person

11,068.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 02262M605

1

Name of reporting person

AULT LIFE SCIENCES FUND, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 61.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 61.00

11

Aggregate amount beneficially owned by each reporting person

61.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Alzamend Neuro, Inc.
(c)	Address of Issuer's Principal Executive Offices: 480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GEORGIA , 30326.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 is amended and restated in its entirety as follows: The securities of the Issuer purchased by each of Hyperscale Data, Ault Life Sciences and Ault Life Sciences Fund were purchased with working capital. The securities of the Issuer acquired by Ault Lending were acquired with working capital. The Shares purchased by Messrs. Ault, Horne and Katzoff were purchased with personal funds. The stock options owned by Messrs. Ault, Horne, Nisser, Cragun and Katzoff were awarded to them in their capacities as officers and/or directors of the Issuer. The aggregate purchase price of the warrants currently exercisable into 12 Shares owned directly by Ault Alliance is approximately $0. The aggregate purchase price of the 11,068 Shares owned directly by Ault Life Sciences is approximately $7,970. The aggregate purchase price of the 61 Shares owned directly by Ault Life Sciences Fund is approximately $123,707. The aggregate purchase price of the 68,848 Shares owned directly by Ault Lending is approximately $159,727. The aggregate purchase price of the approximate 143.24 shares of Series B convertible preferred stock (the "Series B Convertible Preferred Stock") and warrants currently exercisable (subject to beneficial ownership limitations contained therein) into 23,334 Shares owned directly by Ault Lending is approximately $143,245. The aggregate purchase price of the 1,843 Shares owned directly by Mr. Ault is approximately $1,179. The aggregate purchase price of the 3,333 Shares owned directly by Mr. Horne is approximately $14,028. The aggregate purchase price of the 615 Shares owned directly by Mr. Katzoff is approximately $53,374.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) is hereby amended and restated in its entirety as follows: The aggregate percentage of Shares reported beneficially owned by the Reporting Person is based upon 3,739,861 Shares outstanding as of October 7, 2025, which is the total number of Shares outstanding as reported by the Issuer to the Reporting Persons. As of the date hereof, Mr. Ault may be deemed to beneficially own 166,909 Shares, consisting of (i) 1,843 Shares held directly by him, (ii) 61,743 Shares underlying shares of Series B Convertible Preferred Stock held by Ault Lending, (iii) 23,334 Shares underlying currently exercisable warrants held by Ault Lending, (iv) 68,848 Shares held by Ault Lending, (v) 11,068 Shares held by Ault Life Sciences, (vi) 61 Shares held by Ault Life Sciences Fund, and (vii) 12 Shares underlying currently exercisable warrants held by Hyperscale Data. Mr. Ault may be deemed to beneficially own the Shares beneficially owned by Hyperscale Data, Ault Life Sciences, Ault Life Sciences Fund and Ault Lending by virtue of his relationships with such entities described in Item 2. Percentage: Approximately 4.4%. As of the date hereof, Mr. Horne may be deemed to beneficially own 3,518 Shares, consisting of (i) 3,333 Shares held directly by him and (ii) 185 Shares underlying stock options currently exercisable or exercisable within 60 days. Percentage: Approximately 0.1%. As of the date hereof, Mr. Nisser may be deemed to beneficially own 926 Shares, consisting of Shares underlying stock options currently exercisable or exercisable within 60 days. Percentage: Approximately 0.0%. As of the date hereof, Mr. Cragun may be deemed to beneficially own 1,111 Shares, consisting of Shares underlying stock options currently exercisable or exercisable within 60 days. Percentage: Approximately 0.0%. As of the date hereof, Mr. Katzoff may be deemed to beneficially own 1,726 Shares, consisting of (i) 615 Shares held directly by him and (ii) 1,111 Shares underlying stock options currently exercisable or exercisable within 60 days. Percentage: Approximately 0.0%. As of the date hereof, Hyperscale Data may be deemed to beneficially own 153,937 Shares, consisting of (i) 12 Shares underlying currently exercisable warrants held directly by it, (ii) 61,743 Shares underlying shares of Series B Convertible Preferred Stock held by Ault Lending, (iii) 23,334 Shares underlying currently exercisable warrants held by Ault Lending, and (iv) 68,848 Shares held by Ault Lending. Hyperscale Data may be deemed to beneficially own the Shares beneficially owned by Ault Lending by virtue of its relationship with such entity described in Item 2. Percentage: Approximately 4.0%. As of the date hereof, Ault Lending may be deemed to beneficially own 153,925 Shares, consisting of (i) 68,848 Shares held directly by it, (ii) 61,743 Shares underlying shares of Series B Convertible Preferred Stock held directly by it, and (iii) 23,334 Shares underlying currently exercisable warrants held directly by it. Percentage: Approximately 4.0%. As of the date hereof, Ault Life Sciences may be deemed to beneficially own 11,068 Shares held directly by it. Percentage: Approximately 0.3%. As of the date hereof, Ault Life Sciences Fund may be deemed to beneficially own 61 Shares held directly by it. Percentage: Approximately 0.0%.
(b)	Item 5(b) is hereby amended and restated in its entirety as follows: Mr. Ault: 1. Sole power to vote or direct vote: 1,843 2. Shared power to vote or direct vote: 165,066 3. Sole power to dispose or direct the disposition: 1,843 4. Shared power to dispose or direct the disposition: 165,066 Mr. Horne: 1. Sole power to vote or direct vote: 3,518 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 3,518 4. Shared power to dispose or direct the disposition: 0 Mr. Nisser: 1. Sole power to vote or direct vote: 926 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 926 4. Shared power to dispose or direct the disposition: 0 Mr. Cragun: 1. Sole power to vote or direct vote: 1,111 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 1,111 4. Shared power to dispose or direct the disposition: 0 Mr. Katzoff: 1. Sole power to vote or direct vote: 1,726 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 1,726 4. Shared power to dispose or direct the disposition: 0 Hyperscale Data: 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 153,937 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 153,937 Ault Lending: 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 153,925 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 153,925 Ault Life Sciences: 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 11,068 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 11,068 Ault Life Sciences Fund: 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 61 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 61
(c)	Item 5(c) is amended and restated in its entirety as follows: None of the Reporting Persons have engaged in any transactions in the Shares during the past 60 days except as set forth in Exhibit 1 hereto.
(e)	October 7, 2025
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Transactions in the Securities of the Issuer During the Past 60 Days

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MILTON C. AULT, III

Signature:	/s/ Milton C. Ault, III
Name/Title:	Individual
Date:	10/07/2025

WILLIAM B. HORNE

Signature:	/s/ William B. Horne
Name/Title:	Individual
Date:	10/07/2025

HENRY C.W. NISSER

Signature:	/s/ Henry C. Nisser
Name/Title:	Individual
Date:	10/07/2025

KENNETH S. CRAGUN

Signature:	/s/ Kenneth S. Cragun
Name/Title:	Individual
Date:	10/07/2025

DAVID J. KATZOFF

Signature:	/s/ David J. Katzoff
Name/Title:	Individual
Date:	10/07/2025

HYPERSCALE DATA, INC.

Signature:	/s/ Milton C. Ault, III
Name/Title:	Executive Chairman
Date:	10/07/2025

AULT LENDING, LLC

Signature:	/s/ David J. Katzoff
Name/Title:	Manager
Date:	10/07/2025

AULT LIFE SCIENCES, INC.

Signature:	/s/ Milton C. Ault, III
Name/Title:	Chief Executive Officer
Date:	10/07/2025

AULT LIFE SCIENCES FUND, LLC

Signature:	/s/ Milton C. Ault, III
Name/Title:	Managing Member
Date:	10/07/2025